^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bendamustine oral (EX-204)

    i
    Other names: EX-204
    Associations

    News

    Trials
    Company:
    Exinda Therap
    Drug class:
    Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo. (PubMed, Cancers (Basel))
    Background/Objectives: Bendamustine (BEN) combined with rituximab (RTX) remains a standard first-line therapy for transplant-ineligible patients with newly diagnosed mantle cell lymphoma (MCL)... Our findings support the efficacy of oral BEN as both a monotherapy and as part of an all-oral treatment regimen for MCL. These results warrant further investigation into the clinical potential of oral BEN, particularly in combination with targeted agents.
    Preclinical • Journal
    |
    ANXA5 (Annexin A5)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • bendamustine oral (EX-204)